Suppr超能文献

一氧化氮在肝素诱导的缺氧性肺血管重塑减弱中的作用。

Role of nitric oxide in heparin-induced attenuation of hypoxic pulmonary vascular remodeling.

作者信息

Horstman Damian J, Fischer Lars G, Kouretas Peter C, Hannan Robert L, Rich George F

机构信息

Department of Biomedical Engineering, University of Virginia Health System, Charlottesville 22908, USA.

出版信息

J Appl Physiol (1985). 2002 May;92(5):2012-8. doi: 10.1152/japplphysiol.00664.2001.

Abstract

Heparin and nitric oxide (NO) attenuate changes to the pulmonary vasculature caused by prolonged hypoxia. Heparin may increase NO; therefore, we hypothesized that heparin may attenuate hypoxia-induced pulmonary vascular remodeling via a NO-mediated mechanism. In vivo, rats were exposed to normoxia (N) or hypoxia (H; 10% O(2)) with or without heparin (1,200 U x kg-1 x day-1) and/or the NO synthase (NOS) inhibitor Nomega-nitro-L-arginine methyl ester (L-NAME; 20 mg x kg-1 x day-1) for 3 days or 3 wk. Heparin attenuated increases in pulmonary arterial pressure, the percentage of muscular pulmonary vessels, and their medial thickness induced by 3 wk of H. Importantly, although L-NAME alone had no effect, it prevented these effects of heparin on vascular remodeling. In H lungs, heparin increased NOS activity and cGMP levels at 3 days and 3 wk and endothelial NOS protein expression at 3 days but not at 3 wk. In vitro, heparin (10 and 100 U x kg-1 x ml-1) increased cGMP levels after 10 min and 24 h in N and anoxic (0% O2) endothelial cell-smooth muscle cell (SMC) coculture. SMC proliferation, assessed by 5-bromo-2'-deoxyuridine incorporation during a 3-h incubation period, was decreased by heparin under N, but not anoxic, conditions. The antiproliferative effects of heparin were not altered by L-NAME. In conclusion, the in vivo results suggest that attenuation of hypoxia-induced pulmonary vascular remodeling by heparin is NO mediated. Heparin increases cGMP in vitro; however, the heparin-induced decrease in SMC proliferation in the coculture model appears to be NO independent.

摘要

肝素和一氧化氮(NO)可减轻长期缺氧引起的肺血管系统变化。肝素可能会增加NO;因此,我们推测肝素可能通过NO介导的机制减轻缺氧诱导的肺血管重塑。在体内,将大鼠暴露于常氧(N)或缺氧(H;10% O₂)环境中,同时给予或不给予肝素(1200 U·kg⁻¹·d⁻¹)和/或NO合酶(NOS)抑制剂Nω-硝基-L-精氨酸甲酯(L-NAME;20 mg·kg⁻¹·d⁻¹),持续3天或3周。肝素减轻了3周缺氧诱导的肺动脉压升高、肌性肺血管百分比及其中层厚度增加。重要的是,尽管单独使用L-NAME没有效果,但它阻止了肝素对血管重塑的这些作用。在缺氧肺中,肝素在3天和3周时增加了NOS活性和cGMP水平,在3天时增加了内皮型NOS蛋白表达,但在3周时没有增加。在体外,在常氧和缺氧(0% O₂)内皮细胞-平滑肌细胞(SMC)共培养中,肝素(10和100 U·kg⁻¹·ml⁻¹)在10分钟和24小时后增加了cGMP水平。在常氧而非缺氧条件下,通过在3小时孵育期内掺入5-溴-2'-脱氧尿苷评估的SMC增殖被肝素降低。肝素的抗增殖作用不受L-NAME影响。总之,体内结果表明肝素对缺氧诱导的肺血管重塑的减轻作用是由NO介导的。肝素在体外增加cGMP;然而,在共培养模型中肝素诱导的SMC增殖减少似乎与NO无关。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验